KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deffered Revenue (2016 - 2023)

Halozyme Therapeutics (HALO) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $2.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 20.47% to $2.3 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.3 million, a 20.47% decrease, with the full-year FY2022 number at $2.3 million, down 10.95% from a year prior.
  • Non-Current Deffered Revenue was $2.3 million for Q3 2023 at Halozyme Therapeutics, roughly flat from $2.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $4.0 million in Q4 2020 to a low of $641000.0 in Q3 2020.
  • A 5-year average of $2.5 million and a median of $2.4 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 75.1% in 2019, then skyrocketed 294.7% in 2021.
  • Halozyme Therapeutics' Non-Current Deffered Revenue stood at $1.2 million in 2019, then skyrocketed by 222.85% to $4.0 million in 2020, then tumbled by 37.16% to $2.5 million in 2021, then fell by 10.95% to $2.3 million in 2022, then changed by 0.0% to $2.3 million in 2023.
  • Per Business Quant, the three most recent readings for HALO's Non-Current Deffered Revenue are $2.3 million (Q3 2023), $2.3 million (Q2 2023), and $2.3 million (Q1 2023).